AN2 Therapeutics Secures Financial Runway Through 2029

AN2 Therapeutics raises $40M, cuts net loss to $35.2M, and extends cash runway to 2029. Focus shifts to upcoming clinical data for its boron-based drugs in Chagas disease and M. abscessus.

AN2 Therapeutics has solidified its financial position, providing a clear operational runway into 2029. A recent capital raise, combined with stringent fiscal discipline, has positioned the clinical-stage biopharmaceutical company to advance its pipeline without near-term funding concerns. This shift allows investor attention to focus squarely on upcoming clinical milestones for its boron-based therapeutic candidates.

Capital Infusion and Sharply Reduced Losses

The company bolstered its balance sheet this month with approximately $40 million raised through a private placement. These new funds, added to existing reserves, are deemed sufficient to drive development programs forward. Further strengthening the financial picture, AN2 Therapeutics reported a significantly narrowed net loss of $35.2 million for fiscal year 2025. This marks a substantial improvement from the prior year’s loss of $51.3 million.

A disciplined approach to capital allocation was central to this improvement. Notably, research and development expenses were sharply curtailed, falling from $40.5 million to $24.8 million. Management has executed a strategy of refining the clinical pipeline while maintaining strict control over expenditures.

Upcoming Clinical Catalysts on the Horizon

With a strengthened treasury, the firm is poised to concentrate on generating clinical data. Several key near-term events are scheduled that will be critical for evaluating the pipeline's potential:

• Chagas Disease: Initial data from the Phase 1 study for candidate AN2-502998 are anticipated before the end of the first quarter of 2026.
• M. abscessus Lung Disease: Patient recruitment for a Phase 2 trial is set to commence in the first quarter of 2026.
• Polycythemia Vera (PV): A Phase 2 study is scheduled to begin in the third quarter of 2026, with initial results possible as early as the fourth quarter.
• Oncology: Two new drug candidates are expected to enter development during the course of 2026.

AN2 Therapeutics continues to operate with a lean business model, leveraging strategic partnerships such as its collaboration with the Bill & Melinda Gates Foundation in tuberculosis research. The successful execution of its Phase 2 trials, starting with imminent Chagas disease data, is now the primary factor investors will watch to gauge the equity's future trajectory.